Should Anti-CGRP Monoclonal Antibodies Always Be the Drug of First Choice for Migraine Prophylaxis in Brazil? - a Pharmacoeconomic Study. Headache Med 2024, 15 (3), 170-174. https://doi.org/10.48208/HeadacheMed.2024.34.